Roth MKM Maintains Buy on Cellectar Biosciences, Raises Price Target to $28

Cellectar Biosciences -0.33%

Cellectar Biosciences

CLRB

3.03

-0.33%

Roth MKM analyst Jonathan Aschoff maintains Cellectar Biosciences (NASDAQ: CLRB) with a Buy and raises the price target from $20 to $28.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via